PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ASH international clinical collaboration replicates high cure rate of APL in developing countries

2013-01-14
(Press-News.org) (WASHINGTON) – Data published online today in Blood, the Journal of the American Society of Hematology (ASH) describe the work of an ASH international clinical network collaborative focused on modernizing treatment protocols for patients in the developing world with acute promyeloctyic leukemia (APL) that has drastically improved cure rates in patients in Central and South America, achieving comparable outcomes to those observed in patients in the United States and in Europe.

APL is a rare, aggressive cancer of the blood and bone marrow that can be fatal in a matter of hours or days without prompt diagnosis and treatment. Thanks to the introduction of combination therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy, APL has become a highly curable disease for patients in most developed countries. Although recent clinical trials conducted in the developed world have reported very high rates of complete remission (CR) and long-term disease-free survival (DFS) in patients treated with this regimen (90% achieving CR and 85% achieving DFS, respectively), this progress has not yet reached developing countries, where the reported long-term overall survival for patients with APL is below 60 percent.

Recognizing the need to increase APL survival rates in developing countries, in 2005 ASH founded the International Consortium on Acute Promyelocytic Leukemia (IC-APL). The goal of the IC-APL was to foster collaboration between researchers, clinicians, and laboratory scientists from institutions in developing countries and well-established international cooperative groups based in the United States and in Europe. Founding members of the initiative created the program with the hope that the resulting exchange of clinical expertise and support would ultimately improve the diagnosis and treatment of patients in developing countries with this often deadly hematologic malignancy.

"We chose APL as a model disease for the initiative because of the opportunity to improve patient outcomes in the developing world by collaborating with and learning from colleagues who have already successfully made these strides against this disease," said Eduardo Rego, MD, PhD, founding member of the IC-APL and Professor of Hematology/Oncology at the University of São Paulo in Brazil. "This initiative aims to build the capacity of local clinicians in the developing world to conduct clinical trials by introducing and fostering clinical and laboratory procedures that represent the standard of care for the treatment of acute leukemia in many countries around the world."

As part of the IC-APL, four transitioning countries – Brazil, Chile, Mexico, and Uruguay – were chosen to participate in a registry study modeling a clinical trial evaluating the efficacy and safety of a standard-of-care protocol for APL. During the registry study, which was governed by a panel of acute leukemia experts from Europe, Latin America, and the United States, medical representatives from each participating country received essential clinical trial administration training, including standard patient enrollment, data collection and reporting, administration of therapy, and outcomes reporting. Participants also attended regular face-to-face and online meetings with the expert panel to discuss progress and share data.

Following this extensive training, clinicians and scientists from the four participating countries began their registry trial, enrolling 183 adult patients with a suspected APL diagnosis between June 2006 and September 2010. An important change in the induction therapy protocol in the IC-APL registry study conducted in Brazil, Chile, Mexico, and Uruguay compared to regimens used in trials in developed countries was the replacement of the commonly used anthracycline idarubicin with the less expensive and more readily available drug daunorubicin. Patients enrolled in the trial received combination therapy including oral ATRA in two daily doses until complete remission and daunorubicin given intravenously on days 2, 4, 6, and 8. Throughout the trial, participating sites registered all cases using common clinical record forms in the Pediatric Oncology Network Database (POND) and collaborated with national clinical trial coordinators and reference laboratories to confirm the integrity and accuracy of treatment data.

After approximately three years of follow-up, investigators observed incredibly promising results: 80 percent of patients achieved two-year OS and 91 percent achieved DFS, all with a low cumulative incidence of relapse (4.5%). Early patient mortality (death occurring between diagnosis and first evaluation at 30 days) in the trial was reduced by nearly half compared to historical controls, and overall survival improved by 30 percent. Of the 180 evaluable patients that participated in the four host countries, 153 (85%) achieved complete remission.

After five years of follow-up, 75.4 percent of all patients enrolled and 90.2 percent of those who achieved CR remained alive. Early death occurred in 27 patients (15%). These rates of death are considerably lower than other population-based studies analyzing early mortality of APL patients conducted in the United States and Sweden (17.3% and 29%, respectively), further demonstrating the safety of this treatment combination. The most frequent hematologic toxicity was grade 4 neutropenia (low neutrophil count), which was observed in a small group (3.3%) of patients. No significant toxicities were reported during maintenance therapy and no secondary malignancies were reported. "In a very short time period, we observed an extraordinary increase in survival rates of our participants, who, before this trial, might not have had much hope for survival," said Dr. Rego.

The outstanding patient survival rates observed in the IC-APL trial demonstrate the efficacy of this affordable and readily available treatment protocol and are comparable to those observed in studies conducted in developed countries by both the Spanish group Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA, CR: 92.5% and 90%) and the North American Leukemia Intergroup (CR: 90%).

By refining and standardizing diagnostic procedures and implementing a standard-of-care treatment protocol, members of this innovative ASH collaborative have taken the first step toward significantly improving the prognosis of patients with severe and rapidly fatal diseases, such as APL, in developing countries using affordable and available treatments.

"Our initial success truly demonstrates that when we work closely with colleagues from around the world we can close the gap in treatment outcomes between patients in developed countries and those in developing countries. Our next challenge will be to improve the outcome of patients with other types of acute myeloid leukemias," added Dr. Rego, who also serves as the IC-APL's Brazilian national coordinator. "We are also expanding this initiative to additional countries, where we hope to further integrate education and networking and refine our treatment design to determine if we can achieve improved outcomes and possibly translate this model to other diseases."

Based on the initial success of the IC-APL, its governing body voted to expand the collaborative model to address other subtypes of acute leukemias, beginning with acute myeloid leukemia (AML). To reflect this change, the cooperative group is now called the International Consortium on Acute Leukemia (ICAL). For more information on ICAL, visit the ASH Global Programs website. ###

Blood (www.bloodjournal.org) the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world's largest professional society concerned with the causes and treatment of blood disorders.

ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.



ELSE PRESS RELEASES FROM THIS DATE:

Better care from doctors who are culturally aware

2013-01-14
HIV patients from ethnic minorities receive better quality of care from doctors and other primary healthcare professionals who are the most competent at caring for patients from diverse backgrounds – those who are "culturally competent." These patients also tend to manage both their treatment and condition better, according to a new study¹ by Somnath Saha from Portland VA Medical Center, and the Oregon Health & Science University in the US, and colleagues. Their findings appear in the Journal of General Internal Medicine², published by Springer. The authors explored whether ...

The secret sex life of the penicillin-producing fungus could make it more productive

2013-01-14
New and more effective strains of the fungus used to produce penicillin could be developed after a team of international scientists unearthed the secret sex life of Sir Alexander Fleming's fungus Penicillium chrysogenum (P. chrysogenum). The scientists from The University of Nottingham, Ruhr-University Bochum, The University of Göttingen, and Sandoz GmbH have announced a major breakthrough in our understanding of the sex life of the fungus P. chrysogenum. Their research looks sets to lead to the introduction of new and more effective strains of the world's first antibiotic ...

Parkinson's treatment can trigger creativity

Parkinsons treatment can trigger creativity
2013-01-14
Parkinson's experts across the world have been reporting a remarkable phenomenon — many patients treated with drugs to increase the activity of dopamine in the brain as a therapy for motor symptoms such as tremors and muscle rigidity are developing new creative talents, including painting, sculpting, writing, and more. Prof. Rivka Inzelberg of Tel Aviv University's Sackler Faculty of Medicine first noticed the trend in her own Sheba Medical Center clinic when the usual holiday presents from patients — typically chocolates or similar gifts — took a surprising turn. "Instead, ...

Team finds gene that promotes drug resistance in cancer

2013-01-14
Scientists from the University of Iowa and Brigham Young University (BYU) have identified a gene that may be a target for overcoming drug resistance in cancer. The finding could not only improve prognostic and diagnostic tools for evaluating cancer and monitoring patients' response to treatment but also could lead to new therapies directed at eradicating drug-resistant cancer cells. Drug resistance is a common problem in many metastatic cancers. It leads to failure of chemotherapy treatments and is associated with poor patient outcomes, including rapid relapse and death. The ...

American College of Physicians calls for immunizations for all health care providers

2013-01-14
PHILADELPHIA, January 14, 2013 -- The American College of Physicians (ACP) has approved a policy recommendation that all health care providers (HCPs) be immunized against influenza; diphtheria; hepatitis B; measles, mumps, and rubella; pertussis (whooping cough); and varicella (chickenpox) according to the Advisory Committee on Immunization Practices (ACIP) Adult Immunization Schedule. ACP's policy exempts HCPs for medical reasons or a religious objection to immunization. "These transmissible infectious diseases represent a threat to health care providers and the patients ...

Are some patients too heavy for a new kidney?

2013-01-14
ST. LOUIS – In a research review article published in the American Journal of Nephrology, Saint Louis University investigators examined data from multiple studies to better understand how obesity, an epidemic in the U.S., impacts kidney transplant patients. The authors report that, even as some connections between weight and health outcomes are unknown or contradictory, there is evidence that obese kidney transplant patients don't do as well after surgery, experiencing more adverse outcomes, including wound infections, delayed graft function, graft failure, cardiac disease ...

Noise protection – multifunctional and aesthetical

Noise protection – multifunctional and aesthetical
2013-01-14
Too much noise causes illness. This is as an undisputed fact nowadays, and yet we're still constantly assailed by noise as we go about our daily lives, be it from traffic or voices in large open-plan offices. Noise pollution can be reduced with the help of structural solutions; we've all seen noise barriers along busy roads and train lines, and there are special acoustic structural components, so-called sound absorbers, which are used inside buildings to keep noise levels down. But there's a problem. The construction components used up until now may well be effective at ...

Can acupuncture improve exercise performance and post-exercise recovery?

Can acupuncture improve exercise performance and post-exercise recovery?
2013-01-14
New Rochelle, NY, January 14, 2013—The effects of acute acupuncture applied during exercise on performance factors such as power and blood pressure and on the body's ability to recover post-exercise were evaluated in a review article published in The Journal of Alternative and Complementary Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal website at http://www.liebertpub.com/acm. A review of the literature uncovered four studies designed to test whether a person receiving acupuncture while exercising ...

Stem-cell approach shows promise for Duchenne muscular dystrophy

Stem-cell approach shows promise for Duchenne muscular dystrophy
2013-01-14
CHAMPAIGN, Ill. — Researchers have shown that transplanting stem cells derived from normal mouse blood vessels into the hearts of mice that model the pathology associated with Duchenne muscular dystrophy (DMD) prevents the decrease in heart function associated with DMD. Their findings appear in the journal Stem Cells Translational Medicine. Duchenne muscular dystrophy is a genetic disorder caused by a mutation in the gene for dystrophin, a protein that anchors muscle cells in place when they contract. Without dystrophin, muscle contractions tear cell membranes, leading ...

Social networks may inflate self-esteem, reduce self-control

2013-01-14
PITTSBURGH/NEW YORK—January 14, 2013— Users of Facebook and other social networks should beware of allowing their self-esteem—boosted by "likes" or positive comments from close friends—to influence their behavior: It could reduce their self-control both on and offline, according to an academic paper by researchers at the University of Pittsburgh and Columbia Business School that has recently been published online in the Journal of Consumer Research. Titled "Are Close Friends the Enemy? Online Social Networks, Self-Esteem, and Self-Control," the research paper demonstrates ...

LAST 30 PRESS RELEASES:

Printed skin to replace animal testing

Precision medicine could be possible in the fight against antibiotic resistance

Researchers at the Lewis Katz School of Medicine at Temple University identify new targeted approach to protect neurons against degeneration

Western diet causes inflammation, traditional African food protects

Electrochemical method supports nitrogen circular economy

How researchers are shining a light on kidney disease

Some gut bacteria could make certain drugs less effective

PEPITEM sequence shows effects in psoriasis, comparable to steroid cream

Older teens who start vaping post-high school risk rapid progress to frequent use

Corpse flowers are threatened by spotty recordkeeping

Riding the AI wave toward rapid, precise ocean simulations

Are lifetimes of big appliances really shrinking?

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

[Press-News.org] ASH international clinical collaboration replicates high cure rate of APL in developing countries